Market capitalization | $2.39m |
Enterprise Value | $100.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.21 |
P/S ratio (TTM) P/S ratio | 4.98 |
P/B ratio (TTM) P/B ratio | 0.33 |
Revenue growth (TTM) Revenue growth | -15.91% |
Revenue (TTM) Revenue | $480.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Vascular Biogenics Ltd.:
1 Analyst has issued a forecast Vascular Biogenics Ltd.:
Jun '24 |
+/-
%
|
||
Revenue | 0.48 0.48 |
0%
0%
|
|
Gross Profit | 0.42 0.42 |
0%
0%
|
|
EBITDA | -16 -16 |
0%
0%
|
EBIT (Operating Income) EBIT | -16 -16 |
0%
0%
|
Net Profit | -16 -16 |
0%
0%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
Head office | Israel |
CEO | Kaile Zagger |
Founded | 2014 |
Website | www.notablelabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.